blcm-20200529

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

The University of Texas M.D. Anderson Cancer Center (“M.D. Anderson”) notified Bellicum Pharmaceuticals, Inc. (the “Company”) of its decision to resume, on a phased basis, selected research and manufacturing activities, including activity in the manufacturing facility in which the product candidates for the Company’s clinical development programs are manufactured. The Company is providing this update in light of its April 17, 2020 disclosure announcing that M.D. Anderson had informed the Company of its decision to temporarily halt such research and manufacturing activities. Whether M.D. Anderson continues manufacturing without interruption or again temporarily halts activity in its effort to mitigate the impact of COVID-19 on its patients and employees is within the sole discretion of M.D. Anderson.

On May 29, 2020, the U.S. District Court for the Southern District of Texas, Houston Division granted the Company’s motion to dismiss with prejudice in the purported class action complaint filed on February 6, 2018 against the Company and certain of its current and former employees, captioned Nipun Kakkar v. Bellicum Pharmaceuticals, Inc., Rick Fair and Alan Musso. As previously reported, the complaint alleged that the Company and members of its management violated federal securities laws by making allegedly false and misleading statements. The court’s written order dismissed the case in its entirety with prejudice, resulting in a termination of all claims. The plaintiffs have not indicated whether they will appeal the dismissal.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cover	May 29, 2020
Cover [Abstract]
Document Type	8-K
Document Period End Date	May 29, 2020
Entity Registrant Name	Bellicum Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-36783
Entity Tax Identification Number	20-1450200
Entity Address, Address Line One	2130 W. Holcombe Blvd.
Entity Address, Address Line Two	Ste. 800
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77030
City Area Code	832
Local Phone Number	384-1100
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	BLCM
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001358403
Amendment Flag	false

Cover

May 29, 2020

Cover [Abstract]

Document Type

8-K

Document Period End Date

May 29, 2020

Entity Registrant Name

Bellicum Pharmaceuticals, Inc.

Entity Incorporation, State or Country Code

Entity File Number

001-36783